Positive Association of the β Fibrinogen H1/H2 Gene Variation to Basal Fibrinogen Levels and to the Increase in Fibrinogen Concentration during Acute Phase Reaction but not to Coronary Artery Disease and Myocardial Infarction

Summary

Background: Fibrinogen has been demonstrated to be an independent risk factor of cardiovascular disease. The absence of the Haelll cutting site (H2 allele) of an H1/H2 gene variation in the promoter region of the (β fibrinogen gene was associated with increased levels of fibrinogen. Methods and Results: In the present study, the effects of the H1/H2 gene variation not only on plasma fibrinogen concentrations but also on coronary artery disease (CAD) and myocardial infarction (MI) were investigated in 923 individuals who underwent coronary angiography for diagnostic purposes. Relation of the H1/H2 genotype to fibrinogen plasma levels: A strong association was observed between the H1/H2 gene variation and fibrinogen levels. The differences in fibrinogen plasma levels between H2H2 and H1H1 homozygotes were almost threefold more pronounced within subjects with clinical chemical signs of an acute phase reaction (CRP ≥ 7.5 mg/1) than within a subgroup of subjects without these signs (CRP < 7.5 mg/1) (median of CRP distribution: 7.5 mg/1). In 207 patients who underwent aortocoronary bypass surgery plasma fibrinogen levels were almost identical directly after surgery. Two days after operation fibrinogen increased to clearly higher levels in H2H2 homozygotes than in H1H2 and H1H1 genotypes, whereas almost the same maximal increases in fibrinogen concentrations were reached 3-4 days after surgery in all individuals. Relation of the H1/H2 genotype to CAD and MI. Whereas in the total population the plasma fibrinogen concentrations were strongly associated with smoking, CAD and MI, an association of the H1/H2 gene variation to CAD and MI was not detected. However, mean age at first MI of H2H2 individuals (62.9 years) was clearly higher than of H1H2 genotypes (56.9 years) and of H1H1 subjects (56.4 years). In addition, in a subgroup of individuals with a higher risk of MI by either high apoB and/or low apoAl plasma levels the portion of MI patients was clearly smaller within H2H2 homozygotes than within H1H2 or H1H1 genotypes, although – also in these high risk groups – mean age at first MI of H2H2 individuals were higher than of the other two genotypes.

Conclusions: Obviously, the H2 allele of the fibrinogen H1/H2 genotype does not only influence basal fibrinogen concentrations, but particularly also the extent of fibrinogen level increase during acute phase reaction. Whereas the fibrinogen plasma level is positively associated with coronary artery disease and myocardial infarction, the H2 allele - although exhibiting an association with elevated fibrinogen levels - was not positively associated with CAD and MI.

• References

• 1 Meade TW, Mellows S, Brozovic M. et al Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 336: 533-537
• 2 Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 338-342
• 3 ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17
• 4 Wilhelmsen L SvärdsuddK, Korsan-Bengtsen K, Larsson B, Welin L, Tibbliu G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
• 5 Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischaemic heart disease. Circulation 1991; 83: 836-844
• 6 Kannel WB, Wolf P, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA 1987; 258: 1183-1186
• 7 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor a meta-analysis and review of the literature. Ann Intern Med 1993 1993; 118: 956-963
• 8 Fey GH, Fuller GM. Regulation of acute phase gene expression by inflammatory mediators. Mol Biol Med 1987; 04: 323-338
• 9 Balleisen L, Bailey J, Epping PH, Schulte H, van de LooJ. Epidemiology study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemost 1985; 54: 475-479
• 10 Folsom AR. Epidemiology of fibrinogen. Eur Heart J 1995; 16 (supplement A) 21-24
• 11 Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WRS, Stirling Y. Haemostatic variables associated with diabetes and its complication. Br Med J 1979; 02: 964-966
• 12 Abbot RD, Yin YinMA, Ree DM, Yano K. Risk of stroke in male cigarette smokers. N Engl J Med 1986; 315: 717-720
• 13 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: The Scottish heart health Study. J Clin Epidemiol 1990; 43: 913-919
• 14 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlic PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205
• 15 Roy SM, Mukhopadtyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of HepG2 cells with Bβ cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265: 6389-6393
• 16 Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the β fibrinogen gene is associated with plasma fibrinogen levels in smokers and nonsmokers. Thromb Haemost 1991; 65: 487-490
• 17 Green F, Hamsten A, Blombäck M, Humphries S. The role of β-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-920
• 18 Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arterioscl Thromb 1993; 13: 886-891
• 19 Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou JP, Scarabin PY, Bara L, Green F, Cambien F. β-Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996; 93: 440-449
• 20 Gardemann A, Schwartz O, Weiβ T, Katz N, Eberbach A, Hehrlein W, Tillmanns G, Haberbosch W. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated to coronary artery disease and myocardial infarction in low risk patients. Circulation 1995; 92: 2796-2799
• 21 Gensini GG. Coronary arteriography. In: Heart disease. Braunwald E. (ed) Philadelphia: WB Saunders Co; 1980: 352-353
• 22 Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606
• 23 Ernst E, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentrations. Eur Heart J 1995; 16 (supplememt A) 47-53
• 24 Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 82: 2077-2080
• 25 Kattermann R, Jaworek D, Moller G, Assmann G, Bjorkhem I, Svensson L, Borner K, Boerma G, Leijnse B, Desager JP. Multicenter study of a new enzymatic method of cholesterol determination. Clin Chem Clin Biochem 1984; 22: 245-251
• 26 Fink PC, Romer M, Haeckel R, Fateh-Moghadam A, Delanghe J, Gressner AM, Dubs RW. Measurement of proteins with the Behring nephelometer. A multicenter evaluation. J Clin Chem Clin Biochem 1989; 27: 261
• 27 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol (Basel) 1957; 17: 237
• 28 Ross DW, Brecher G, Bessis M. Automation in Hematology. Springer, Berlin, Heidelberg, New York: 1981
• 29 Kawasaki ES. Sample preparation from blood, cells, and other fluids. In: PCR protocols: A guide to methods and applications. Innis MA, Gelfand DH, Sninsky JJ, White T. (eds) Academic Press Inc; San Diego: 1990: 146-152
• 30 Sosef MN, Bosch JG, van OostayenJ, Visser T, Reiber JHC, Rosendaal FR. Relation of plasma coagulation factor VII and fibrinogen to carotid artery intima-media thickness. Thromb Haemost 1994; 72: 250-254
• 31 Koster T, Rosendaal FR, Reitsma PH, van der VeldenPA, Briet E, Vanden-broucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb Haemost 1994; 71: 719-722
• 32 Yu S, Sher B, Kudryk B, Redmann CM. Intracellular assembly of human fibrinogen. J Biol Chem 1983; 258: 13407-13410